While our data reflect only modest changes in NRF2-mediated gene expression, they are highly encouraging and suggest that treatment with more potent NRF2 activators over an extended period may lead to more significant, favorable physiological responses in patients with sickle cell disease. The gene discussed is NFE2L2; the disease is sickle cell disease.